Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02412670 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
A Phase 2 study, sponsored by ECOG-ACRIN Cancer Research Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT02412670 is a Phase 2 study that has completed, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 36 participants.
The verdict
NCT02412670, a Phase 2 study, has completed, sponsored by ECOG-ACRIN Cancer Research Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This phase II trial studies how well giving chemotherapy before surgery works in treating patients with aggressive upper urinary tract cancer. Drugs used in chemotherapy, such as methotrexate, vinblastine, doxorubicin hydrochloride, cisplatin, gemcitabine hydrochloride, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Removing the affected upper urinary tract by surgery is the recommended treatment for upper urinary tract cancer, but can cause loss of kidney function and prevent patients from being able to receive chemotherapy after surgery. Giving chemotherapy before surgery, when the kidneys are working at their maximum, may allow less tissue to be removed during surgery and may be more effective in treating patients with high grade upper urinary tract cancer.
Interventions
- DRUG Cisplatin
- DRUG Doxorubicin
- DRUG Gemcitabine
- DRUG Methotrexate
- DRUG Vinblastine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2015-08-27 |
| Est. Completion | 2022-05-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02412670
The ClinicalTrials.gov registry entry for NCT02412670 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT02412670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02412670 about?
NCT02412670 is a clinical study titled "Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer". This phase II trial studies how well giving chemotherapy before surgery works in treating patients with aggressive upper urinary tract cancer. Drugs used in chemotherapy, such as methotrexate, vinblastine, doxorubicin hydrochloride, cisplatin, gemcitabine hydrochloride, and carboplatin, work in diff...
What is the current status of trial NCT02412670?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2015-08-27. Estimated completion is 2022-05-10.
What interventions are being tested in trial NCT02412670?
The interventions under investigation include: Cisplatin (DRUG), Doxorubicin (DRUG), Gemcitabine (DRUG), Methotrexate (DRUG), Vinblastine (DRUG).
Who is sponsoring clinical trial NCT02412670?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.